These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 27425814)

  • 1. High frequency of gene mutations in metastatic prostate cancer.
    Wilkinson E
    Lancet Oncol; 2016 Aug; 17(8):e326. PubMed ID: 27425814
    [No Abstract]   [Full Text] [Related]  

  • 2. Integrative sequencing of metastatic cancer.
    Venkatesan P
    Lancet Oncol; 2017 Sep; 18(9):e518. PubMed ID: 28803795
    [No Abstract]   [Full Text] [Related]  

  • 3. The Search for the Missing Heritability of Prostate Cancer.
    Walsh PC
    Eur Urol; 2017 Nov; 72(5):657-659. PubMed ID: 28442163
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Patient-Level DNA Damage and Repair Pathway Profiles and Prognosis After Prostatectomy for High-Risk Prostate Cancer.
    Evans JR; Zhao SG; Chang SL; Tomlins SA; Erho N; Sboner A; Schiewer MJ; Spratt DE; Kothari V; Klein EA; Den RB; Dicker AP; Karnes RJ; Yu X; Nguyen PL; Rubin MA; de Bono J; Knudsen KE; Davicioni E; Feng FY
    JAMA Oncol; 2016 Apr; 2(4):471-80. PubMed ID: 26746117
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Molecular high throughput research in prostate carcinoma].
    Schlomm T; Sültmann H; Poustka A; Sauter G; Hellwinkel OJ; Huland H
    Urologe A; 2007 Sep; 46(9):1097-100. PubMed ID: 17628772
    [No Abstract]   [Full Text] [Related]  

  • 6. Endosomal gene expression: a new indicator for prostate cancer patient prognosis?
    Johnson IR; Parkinson-Lawrence EJ; Keegan H; Spillane CD; Barry-O'Crowley J; Watson WR; Selemidis S; Butler LM; O'Leary JJ; Brooks DA
    Oncotarget; 2015 Nov; 6(35):37919-29. PubMed ID: 26473288
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting PARP in Prostate Cancer: Novelty, Pitfalls, and Promise.
    Palmbos PL; Hussain MH
    Oncology (Williston Park); 2016 May; 30(5):377-85. PubMed ID: 27188668
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A novel non-canonical Wnt signature for prostate cancer aggressiveness.
    Sandsmark E; Hansen AF; Selnæs KM; Bertilsson H; Bofin AM; Wright AJ; Viset T; Richardsen E; Drabløs F; Bathen TF; Tessem MB; Rye MB
    Oncotarget; 2017 Feb; 8(6):9572-9586. PubMed ID: 28030815
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genetic profile of ductal adenocarcinoma of the prostate.
    Seipel AH; Whitington T; Delahunt B; Samaratunga H; Mayrhofer M; Wiklund P; Grönberg H; Lindberg J; Egevad L
    Hum Pathol; 2017 Nov; 69():1-7. PubMed ID: 28457729
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genetic variants in RhoA and ROCK1 genes are associated with the development, progression and prognosis of prostate cancer.
    Liu K; Li X; Wang J; Wang Y; Dong H; Li J
    Oncotarget; 2017 Mar; 8(12):19298-19309. PubMed ID: 28184030
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular classification of prostate adenocarcinoma by the integrated somatic mutation profiles and molecular network.
    Yang L; Wang S; Zhou M; Chen X; Jiang W; Zuo Y; Lv Y
    Sci Rep; 2017 Apr; 7(1):738. PubMed ID: 28389666
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Searching for candidate genes in familial BRCAX mutation carriers with prostate cancer.
    Hunter SM; Rowley SM; Clouston D; ; Li J; Lupat R; Krishnananthan N; Risbridger G; Taylor R; Bolton D; Campbell IG; Thorne H
    Urol Oncol; 2016 Mar; 34(3):120.e9-16. PubMed ID: 26585945
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Somatic molecular subtyping of prostate tumors from HOXB13 G84E carriers.
    Lotan TL; Torres A; Zhang M; Tosoian JJ; Guedes LB; Fedor H; Hicks J; Ewing CM; Isaacs SD; Johng D; De Marzo AM; Isaacs WB
    Oncotarget; 2017 Apr; 8(14):22772-22782. PubMed ID: 28186998
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genetic variations in TP53 binding sites are predictors of clinical outcomes in prostate cancer patients.
    Lin VC; Huang CY; Lee YC; Yu CC; Chang TY; Lu TL; Huang SP; Bao BY
    Arch Toxicol; 2014 Apr; 88(4):901-11. PubMed ID: 24448834
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Identification of the molecular bases of metastasis for the development of new therapy strategies of metastatic prostate carcinoma].
    Schenck M; Boergermann C; vom Dorp F; Busch Y; Groneberg M; Wilker B; Keitsch S; Moyrer S; Schmid KW; Stuschke M; Ruebben H; Gulbins E
    Urologe A; 2007 Sep; 46(9):1261-2. PubMed ID: 17668173
    [No Abstract]   [Full Text] [Related]  

  • 16. Genetic classifiers for prostate cancer: A new era on the horizon?
    Hong SK
    Korean J Urol; 2015 Sep; 56(9):605-6. PubMed ID: 26366271
    [No Abstract]   [Full Text] [Related]  

  • 17. Beyond bad luck: induced mutations and hallmarks of cancer.
    Kelly-Irving M; Delpierre C; Vineis P
    Lancet Oncol; 2017 Aug; 18(8):999-1000. PubMed ID: 28759371
    [No Abstract]   [Full Text] [Related]  

  • 18. Prostate cancer: A step to identifying men at high risk of metastatic disease.
    Thoma C
    Nat Rev Urol; 2016 Sep; 13(9):493. PubMed ID: 27455893
    [No Abstract]   [Full Text] [Related]  

  • 19. Practical Methods for Integrating Genetic Testing Into Clinical Practice for Advanced Prostate Cancer.
    Cheng H; Powers J; Schaffer K; Sartor O
    Am Soc Clin Oncol Educ Book; 2018 May; 38():372-381. PubMed ID: 30231311
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Personalising the treatment of prostate cancer.
    Gunjur A
    Lancet Oncol; 2015 Dec; 16(16):e592. PubMed ID: 26549591
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.